BioCentury
ARTICLE | Company News

Spectrum Pharmaceuticals, Altair deal

February 7, 2005 8:00 AM UTC

Spectrum received exclusive worldwide rights develop and market ALTI's RenaZorb. The lanthanum-based phosphate binding compound is in preclinical development to control phosphate levels in patients w...